Drug development has never been this close to making a clinical impact

Poor translatability of traditional in vitro models has a major impact on drug attrition leading to only 8% of new drugs that show preclinical efficacy progressing after Phase I trials. It’s time to rethink convention.

HUB Organoids closely recapitulate patient pathobiology, providing superior preclinical models for your compound testing and closing the gap to clinical trials. HUB Organoids can support decision-making at every step of your drug development pipeline and help you bring life-changing treatments to patients.

Service portfolio

Drug screening services

Leverage the predictive power of HUB Organoids to select the most promising clinical candidates with confidence

discover more

Custom model and assay development

Innovate novel disease models and assays and bring your research to the next level

discover more

Clinical trials in a dish

Accurately stratify and customize patient treatment with our co-clinical testing platform

learn more

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology


Drug discovery to clinical trials in five years!

Read our proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.

learn more get a quote



Recent advancements in patient-derived organoid technology and their impact on drug development

watch now



Patient-derived organoids predict clinical response: a patient in the lab

download now


HUB Organoids® and Yamaha Motor announce their collaboration combining their proprietary technologies


Application of HUB Organoids in immuno-oncology drug development

download now


Get in touch

Discover the transformative potential of our technology with a free consultation with an expert

Have any questions?

contact us